Ortho Retin-A approval
Lower dose (.025%) cream formulation approved by FDA on Sept. 23. The new product joins .1% crea, .025% gel and .05% liquid formulations. No new indications were approved. New "milder" cream will be introduced by the end of the year, Ortho said. The company has scheduled a press conference for Oct. 18 to announce the approval and to report on new Retin-A studies.
You may also be interested in...
The head of the US Food and Drug Administration praised the life-saving work of device center staff in response to the coronavirus pandemic.
Decision on Regeneron’s Ebola virus therapy, which uses a similar monoclonal antibody cocktail approach as the company’s COVID-19 therapy candidate, stands out among the 10 user fee goal dates in the coming month.
Investigative reports from the House Oversight and Reform Committee recount well-known records of significant price increases for the drugs, the lack of pricing restraints in the US relative to markets abroad, tactics used to protect the drugs from generic competition and the 'return on investment' from manufacturer assistance programs.